JP2006249089A5 - - Google Patents

Download PDF

Info

Publication number
JP2006249089A5
JP2006249089A5 JP2006065731A JP2006065731A JP2006249089A5 JP 2006249089 A5 JP2006249089 A5 JP 2006249089A5 JP 2006065731 A JP2006065731 A JP 2006065731A JP 2006065731 A JP2006065731 A JP 2006065731A JP 2006249089 A5 JP2006249089 A5 JP 2006249089A5
Authority
JP
Japan
Prior art keywords
ethyl
imidazo
pyridin
carbonyl
dimethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006065731A
Other languages
English (en)
Japanese (ja)
Other versions
JP5069415B2 (ja
JP2006249089A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2006249089A publication Critical patent/JP2006249089A/ja
Publication of JP2006249089A5 publication Critical patent/JP2006249089A5/ja
Application granted granted Critical
Publication of JP5069415B2 publication Critical patent/JP5069415B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2006065731A 2005-03-11 2006-03-10 結晶形態のイミダゾール誘導体 Active JP5069415B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66059205P 2005-03-11 2005-03-11
US60/660,592 2005-03-11

Publications (3)

Publication Number Publication Date
JP2006249089A JP2006249089A (ja) 2006-09-21
JP2006249089A5 true JP2006249089A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2009-04-16
JP5069415B2 JP5069415B2 (ja) 2012-11-07

Family

ID=36649530

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006065731A Active JP5069415B2 (ja) 2005-03-11 2006-03-10 結晶形態のイミダゾール誘導体

Country Status (21)

Country Link
US (1) US7960407B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP1861400B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP5069415B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR100911073B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN101137656B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (1) AR055567A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE469150T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2006221699A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BRPI0608819B8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2600510C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE602006014516D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2344310T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL185145A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN2014DN09939A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX2007011110A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL300944I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL1861400T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2357968C1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TW200643021A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2006095268A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA200707568B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009295308A1 (en) 2008-09-25 2010-04-01 Merck Canada Inc. Beta-carboline sulphonylurea derivatives as EP4 receptor antagonists
MX345032B (es) 2009-04-22 2017-01-12 Raqualia Pharma Inc Antagonistas del receptor ep4 para el tratamiento de cáncer.
EP2538978B1 (en) 2010-02-22 2016-09-07 RaQualia Pharma Inc. Use of an ep4 receptor antagonist in the treatment of allergic contact dermatitis and psoriasis
RU2451680C1 (ru) 2011-02-21 2012-05-27 Общество С Ограниченной Ответственностью "Научно-Исследовательская Компания "Медбиофарм" Клатратный комплекс циклодекстрина или арабиногалактана с 9-фенил-симм-октагидроселеноксантеном, способ его получения (варианты), фармацевтическая композиция и лекарственное средство
RU2464042C1 (ru) * 2011-03-31 2012-10-20 Общество С Ограниченной Ответственностью "Научно-Исследовательская Компания "Медбиофарм" КЛАТРАТНЫЙ КОМПЛЕКС β-ЦИКЛОДЕКСТРИНА С ПРОИЗВОДНЫМ 5-ГИДРОКСИ-4-АМИНОМЕТИЛ-1-ЦИКЛОГЕКСИЛ(ИЛИ ЦИКЛОГЕПТИЛ)-3-АЛКОКСИКАРБОНИЛИНДОЛА, СПОСОБ ЕГО ПОЛУЧЕНИЯ (ВАРИАНТЫ), ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И ЛЕКАРСТВЕННОЕ СРЕДСТВО
BR112015023663A2 (pt) * 2013-03-19 2020-10-20 Askat Inc. uso de um composto com atividade antagonística de ep4 ou um sal farmaceuticamente aceitável deste, uso de um composto da fórmula (i), (ii), (iii), (iv), (va) ou (vb) ou um sal farmaceuticamente aceitável deste, composição farmacêutica para o tratamento de doença de cartilagem, método para o tratamento de doenças de cartilagem em um indivíduo animal, incluindo um indivíduo mamífero e composto da fórmula (i), (ii),(iii), (iv), (va) ou (vb) ou um sal farmaceuticamente aceitável deste
US10391086B2 (en) 2013-03-19 2019-08-27 Askat Inc. Use of EP4 receptor antagonists in the treatment of cartilage disease
AU2015227059B2 (en) * 2014-03-06 2018-11-15 Aratana Therapeutics, Inc. Compositions of grapiprant and methods for using the same
CN107759590A (zh) 2014-03-06 2018-03-06 阿莱塔纳治疗学股份有限公司 Grapiprant的结晶形式
US12109218B2 (en) 2014-12-09 2024-10-08 Aratana Therapeutics, Inc. Compositions of grapiprant and methods for using the same
US10342785B2 (en) 2016-11-04 2019-07-09 Askat Inc. Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer
AU2019255196A1 (en) 2018-04-16 2020-11-12 Arrys Therapeutics, Inc. EP4 inhibitors and use thereof
US10239885B1 (en) 2018-06-18 2019-03-26 Avista Pharma Solutions, Inc. Compound 1-[2-[4-(2-ethyl-6,8-dimethylimidazo[1,2-α]pyrazin-3-yl)phenyl]ethyl]-3-(p-tolylsulfonyl)urea as a prostaglandin EP4 receptor antagonist
CN113301896A (zh) * 2018-07-11 2021-08-24 阿瑞斯医疗有限公司 Ep4抑制剂和其合成
WO2020014465A1 (en) 2018-07-11 2020-01-16 Arrys Therapeutics, Inc. Polymorphic compounds and uses thereof
MX2021009082A (es) 2019-01-30 2021-09-08 Avista Pharma Solutions Inc Compuestos quimicos.
MX2021009251A (es) 2019-01-30 2021-09-21 Avista Pharma Solutions Inc Proceso de sintesis y nuevos compuestos intermedios.
US11254675B2 (en) 2019-08-12 2022-02-22 Cadila Healthcare Limited Process for preparation of grapiprant
WO2021226162A1 (en) 2020-05-05 2021-11-11 Arrys Therapeutics, Inc. Ep4 antagonists and their use in the treatment of proliferative diseases
JP2024526952A (ja) * 2021-07-30 2024-07-19 ラクオリア創薬株式会社 結晶形
CN116478155B (zh) * 2022-01-17 2025-06-13 洛阳惠中兽药有限公司 一种格拉匹伦及其中间体的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL110296A (en) * 1993-07-16 1999-12-31 Smithkline Beecham Corp Imidazole compounds process for their preparation and pharmaceutical compositions containing them
HN2001000224A (es) * 2000-10-19 2002-06-13 Pfizer Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
CN100579518C (zh) * 2002-04-12 2010-01-13 美国辉瑞有限公司 Ep4受体配体在制备治疗il-6相关疾病的药物中的应用

Similar Documents

Publication Publication Date Title
JP2006249089A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA2600510A1 (en) Crystal forms of an imidazole derivative
RU2014105881A (ru) Ансольваты солей норибогаина
ME02275B (me) Polimorfni oblik rotigotina
RU2598606C3 (ru) Кристаллическая тозилатная соль (8s,9r)-5-фтор-8-(4-фторфенил)-9-(1-метил-1н-1,2,4-триазол-5-ил)-8-9-дигидро-2н-пиридо[4,3,2-de]фталазин-3(7н)-она
JP2009536176A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU2009122241A (ru) Твердые формы рацемического илапразола
JP2019503365A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2010514806A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2011522816A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2011528658A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2009517411A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2014526503A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO2019177975A1 (en) Antibiotics effective for gram-negative pathogens
JP2010514807A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2012533565A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2016503010A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2011527333A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2012502037A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI3710000T3 (fi) Tradipitantti käytettäväksi gastropareesin hoidossa
JP2023175694A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU2009133262A (ru) Нападизилатная соль антагониста мускаринового мз-рецептора
HRP20171511T1 (hr) Ivabradin-hidroklorid, oblik iv
JP2021073257A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2015522037A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)